Tonix Pharmaceuticals (TNXP) Life Sciences Virtual Investor Conference summary

Strategic overview and pipeline

• Fast Track designation granted for lead candidate TNX-102SL, with FDA decision expected August 15, 2025.

• Two marketed migraine products, Zembrace and Tosymra, support commercial operations.

• Rich pipeline includes programs for fibromyalgia, acute stress disorder, cocaine intoxication, and vaccines.

• Strategic partnerships and internal R&D capabilities drive innovation.

• Cash runway projected into Q1 2026, with recent debt repayment and reduced annual spending.

Lead program: TNX-102SL for fibromyalgia

• TNX-102SL is a sublingual cyclobenzaprine tablet targeting restorative sleep in fibromyalgia.

• Three phase III trials completed; two showed statistical significance, one confounded by COVID.

• Demonstrated durable benefit and improved tolerability versus existing treatments.

• Market research indicates high unmet need and strong physician interest.

• Patents protect formulation until 2034 in the U.S., withstanding generic challenges.

Additional pipeline and research

• Acute stress disorder study for TNX-102SL to begin at UNC, funded by Department of Defense.

• TNX-1300 for cocaine intoxication showed >90% reduction in blood cocaine in phase II.

• TNX-1500, an anti-CD40 ligand antibody, targets organ transplant rejection and autoimmune diseases.

• TNX-801 vaccine for smallpox/mpox in development, with advanced manufacturing capabilities.

• $34 million Department of Defense contract supports broad-spectrum antiviral program.